CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

Teva Pharmaceuticals to acquire BioXcel assets for up to $125m

Positive
AI Analysis

Summary

Teva Pharmaceuticals announced a bid to acquire neuroscience assets from BioXcel Therapeutics for up to $125 million. The transaction represents a strategic expansion of Teva's neuroscience portfolio.

Importance:7/10
Sentiment:
0.50
M&Aneuroscienceasset acquisition
Related Companies

Read the original article

Published by Pharmaceutical Technology on August 31, 2026 9:32 AM

Read Original